# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $49 price tar...
TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials.
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600.